임상시험

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT: NCT06831136 · RECRUITING

NCT IDNCT06831136

상태RECRUITING

시작일2025-03-26

완료2030-01-20

SponsorThe University of Texas Health Science Center, Houston (OTHER)

First posted2025-02-17

Last updated2026-10-08

간략 요약

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

공식 출처

ClinicalTrials.gov에서 보기 →

데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.